pharmaphorum

JANUARY 17, 2023

Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech Elicio Therapeutics.

Pharmacology 69

Pharmacology Engineering Consulting Leads 69

European Pharmaceutical Review

MARCH 9, 2023

1 These substances “are pharmacologically and biologically active at low doses,” Dr Kishore Hotha, Global Head of Analytical Research & Development at Veranova, explained. ” Highly potent APIs are pharmacologically and biologically active compounds at low doses. internet] GlobeNewswire. Research and Markets. cited 2023Feb].

Safety 98

Safety Pharmacology Training Manufacturing 98

European Pharmaceutical Review

JANUARY 18, 2024

billion in 2022 to $4.1 percent between 2022 and 2032. percent between 2022 and 2032. GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023. percent from $3.2 billion in 2032. million in sales by 2032.

Marketing 98

Marketing Sales Pharmacology Pharma 98

pharmaphorum

JANUARY 16, 2023

Last year, IQVIA predicted that 2022 would be the crunch year for Alzheimer’s therapies: it is with a sense of déjà vu that the exact same prediction is contemplated for 2023. Alzheimer’s is currently the seventh-leading cause of death globally and growing fast. Innovation will power the market.

FDA 85

FDA Healthcare Healthcare Medicine 85

pharmaphorum

JANUARY 26, 2023

2022 was a banner year for genomics. A 2022 study from the Royal College of Physicians and British Pharmacological Society demonstrated the potential of pharmacogenomics, with scientists identifying the genetic cause behind an individual’s drug response for over forty medicines.

Pharmacology 117

Pharmacology Government Leads Physicians 117

Pharmaceutical Technology

NOVEMBER 3, 2022

There, Boehringer had earlier warned of the impending alteplase shortage in April 2022. This is due to aging populations around the world, which leads to an increased risk of such conditions, explains Craig Beavers, PhD, assistant professor at the University of Kentucky’s College of Pharmacy in Lexington.

Medicine 111

Medicine Manufacturing Pharmacology Healthcare 111

European Pharmaceutical Review

JULY 18, 2024

She leads Ipsen’s Early Development Portfolio across the company’s three therapeutic focus areas (Oncology, Rare Disease and Neuroscience). This covers nonclinical drug safety, translational and clinical pharmacology, drug metabolism and pharmacokinetics (DMPK) and pharmacometrics. 2022; 7(93) Maecker et al.

Food and Drug Administration 59

Food and Drug Administration Engineering Pharmacology Side effects 59

Pharmaceutical Technology

FEBRUARY 8, 2023

In 2022, 54% of FDA new drug approvals were for rare diseases , a significant increase in proportion of approvals in the recent years. Blank acknowledged that in many cases, an exclusively paediatric patient population could lead to difficulties with drawing consent for early phase trials.

FDA 105

FDA Patients Pharmacology Pharmaceutical 105

European Pharmaceutical Review

DECEMBER 11, 2023

Known linkers in the RNA field are used to bond together the two pharmacologically active molecular entities and can be applied to multiple oligonucleotide modalities. Research advances are also helping us learn more about how RNA is processed, potentially leading to new strategies to alter dysfunctional RNA. cited 2023July].

Safety 98

Safety Pharmacology Engineering Medical 98

Impetus Digital

AUGUST 2, 2024

In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%. In turn, this can support decision-making and lead to more efficient inventory management and faster delivery times, enhance supply chain visibility and transparency, and avoid overproduction and waste.

Pharma 95

Pharma Manufacturing Medicine Marketing 95

Legacy MEDSearch

AUGUST 25, 2022

Early non-randomized European studies have suggested that this leads to reduced incidence of coronary microvascular obstruction (MVO) [3,4] and smaller infarct size, which are both strongly correlated to improvement in heart failure hospitalizations and reduced mortality following primary PCI [5]. said Olivier Delporte, CEO.

Medical 52

Medical FDA Recruitment Pharmacology 52

European Pharmaceutical Review

MAY 2, 2023

Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. billion in 2022, the average projected return on investment (ROI) in R&D was just 1.2 1,2 In the EU, an estimated 2.7 Available from: [link] Worldwide cancer statistics [Internet].

Patients 105

Patients Medicine Marketing Medical 105

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. 2022 Alzheimer’s Association International Conference. months for donanemab.

Food and Drug Administration 97

Food and Drug Administration Safety Patients Leads 97

European Pharmaceutical Review

JULY 4, 2024

Prior to joining Fieldfisher, Taly spent four years working as in-house counsel for a leading tech company helping launch products across multiple EU markets. 2022 [cited 2024May]. She obtained a degree in physics from MIT prior to attending University of Pennsylvania Law School. researchspace.auckland.ac.nz.

Marketing 103

Marketing Food and Drug Administration Medicine Prescription 103

Pharmaceutical Technology

AUGUST 8, 2022

The digital pill, now marketed by Otsuka Pharmaceuticals, is forecasted to make $27 million in sales in 2022, as per GlobalData. These days, he is leading trials involving a system developed by the digital health company etectRx (pronounced as e-tect-are-ex), which works with investigators who can use such real-time data.

Food and Drug Administration 122

Food and Drug Administration FDA Patients Medicine 122